Zydus receives USFDA tentative approval for Carbidopa and Levodopa Extended-Release Capsules

Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

This combination medication is indicated for the treatment of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, and difficulty moving) and will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 282 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Powered by Capital Market - Live News